Responses
Regular and young investigator award abstracts
Novel single-agent immunotherapies
727 Increased serum levels of EBI3 are associated with poor outcome in hepatocellular carcinoma patients and SRF388, a first-in-class IL-27 blocking antibody, inhibits the growth of murine liver tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
